Table 2 Evaluable patients – clinical stage, pathological response and FDG uptake

Patient	Pre-CRT clinical stage	TRG	Pathological stage	SUV pre (g ml⁻¹)	SUV intra (g ml⁻¹)	Reduction in SUV (%)	MTV pre (g ml⁻¹)	MTV intra (g ml⁻¹)	Reduction in MTV (%)
1	T3N0M0	1	ypT0N0	6.3	5.9	6.4	24.6	19.2	21.9
2	T3N0M0	1	ypTxN0	6.1	3.5	42.6	13.4	3.7	72.1
3	T3N1M0	1	ypT0N0	12.8	11.5	10.4	35.6	34.5	3.2
4	T3N0M0	1	ypT0N0	12.8	12.8	0.0	35.3	22.4	36.5
5	T3N0M0	1	ypT0N0	9.8	9.5	3.0	19.6	20.6	−5.0
6	T3N0M1a	2	ypT3N0	5.1	5.9	−15.7	13.2	16.2	−23.2
7	T3N0M0	2	ypT1N0	19.2	8.9	53.4	80.0	33.0	58.8
8	T3N0M0	2	ypT3N0	21.4	8.3	61.2	61.6	35.3	42.7
9	T3N0M0	2	ypT1N0	19.6	6.8	65.3	46.0	15.5	66.7
10	T3N0M0	3	ypT3N1	19.7	8.6	56.4	48.5	13.7	71.7
11	T3N1M0	3	ypT3N1	10.0	4.8	52.0	25.4	4.7	82.0
12	T3N0M0	3	ypT3N0	9.5	7.0	26.3	25.4	10.1	60.1
13	T3N0M0	3	ypT3N1	20.9	18.3	12.4	95.9	87.6	8.7
14	T3N1M0	3	ypT2N1	12.4	4.7	62.1	22.3	5.5	75.4
15	T3N1M0	3	ypT2N0	12.6	11.7	7.0	4.6	5.8	−25.3
16	T3N0M0	3	ypT3N1	6.4	5.9	7.8	10.2	5.8	43.0
17	T3N0M0	3	ypT3N0	6.0	7.3	−21.7	17.7	13.3	24.9
18	T3N0M0	3	ypT3N0	5.7	4.5	21.1	22.9	28.3	−23.4
19	T2N1M0	3	ypT3N1	9.3	4.7	49.5	46.6	15.9	66.0
20	T3N0M0	3	ypT3N1	4.3	3.8	11.6	7.9	7.1	10.8
21	T3N0M0	3	ypT2N1	5.6	5.7	−1.8	11.6	23.6	−102.5
22	T3N0M0	3	ypT3N0	8.2	8.5	−3.7	21.3	22.6	−6.2
23	T3N0M0	3	ypT3N1	4.4	3.2	27.3	26.0	12.4	52.3
24	T3N0M0	3	ypT3N0	19.1	13.0	31.9	53.3	19.6	63.2
25	T3N0M0	3	ypT3N1	6.2	5.1	17.7	7.6	10.9	−43.3
26	T3N0M0	3	ypT2N1	4.3	4.3	0.0	3.5	4.9	−41.2
27	T3N0M0	3	ypT3N1	8.7	8.7	0.0	103.7	111.3	−7.3
28	T3N0M0	4	ypT3N0	6.2	3.5	43.6	16.9	0.0	100.0
29	T3N0M0	4	ypT4N1	20.8	11.9	42.8	154.0	239.0	−55.2
30	T3N0M0	4	ypT3N1	10.5	10.5	0.0	32.4	58.2	−79.6
31	T3N1M0	4	ypT3N0	7.8	2.9	62.8	49.8	13.9	72.1
32	T3N0M0	4	ypT3N1	5.2	4.8	7.7	19.2	18.9	1.7

CRT=chemoradiation; FDG=fluorodeoxyglucose; intra=during CRT; MTV=metabolic tumour volume; pre=before CRT; SUV=mean maximum standardised uptake value; TRG=tumour regression grade.

Search